JNK3 inhibitors as promising pharmaceuticals with neuroprotective properties

• Published in: Cell adhesion & migration Vol. 18; no. 1; pp. 1 - 11
• Main Authors: Wu, Yibeini, Zhao, Yiling, Guan, Ziman, Esmaeili, Sajjad, Xiao, Zhicheng, Kuriakose, Diji
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.12.2024; Taylor & Francis Group
• Subjects: Apoptosis; inhibitor; JNK3; MAPK signalling pathway; Mitogen-Activated Protein Kinase 10 - physiology; neurodegenerative disease; neuroinflammation; Neuroprotection; Pharmaceutical Preparations; Review; neurodegenerative disease; inhibitor; neuroinflammation; neuroprotection; MAPK signalling pathway; JNK3; oxidative stress; Apoptosis
• ISSN: 1933-6918; 1933-6926
• DOI: 10.1080/19336918.2024.2316576

The intensive study and investigation of neuroprotective therapy for central nervous system (CNS) diseases is ongoing. Due to shared mechanisms of neurodegeneration, a neuroprotective approach might offer benefits across multiple neurological disorders, despite variations in symptoms or injuries. C-Jun N-terminal Kinase 3 (JNK3) is found primarily in the CNS and is involved in physiological processes such as brain development, synapse formation, and memory formation. The potential of JNK3 as a target for pharmacological development holds promise for advancing neuroprotective therapies. Developing small molecule JNK3 inhibitors into drugs with neuroprotective qualities could facilitate neuronal restoration and self-repair. This review focuses on elucidating key neuroprotective mechanisms, exploring the interplay between neurodegenerative diseases and neuroprotection, and discussing advancements in JNK3 inhibitor drug development.